Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer.

PURPOSE To identify , within the framework of a current Phase I trial, whether factors related to intraprostatic cancer lesions (IPLs) or individual patients predict the feasibility of high-dose intraprostatic irradiation. METHODS AND MATERIALS Endorectal coil MRI scans of the prostate from 42 men were evaluated for dominant IPLs. The IPLs, prostate, and critical normal tissues were contoured. Intensity-modulated radiotherapy plans were generated with the goal of delivering 75.6 Gy in 1.8-Gy fractions to the prostate, with IPLs receiving a simultaneous integrated boost of 3.6 Gy per fraction to a total dose of 151.2 Gy, 200% of the prescribed dose and the highest dose cohort in our trial. Rectal and bladder dose constraints were consistent with those outlined in current Radiation Therapy Oncology Group protocols. RESULTS Dominant IPLs were identified in 24 patients (57.1%). Simultaneous integrated boosts (SIB) to 200% of the prescribed dose were achieved in 12 of the 24 patients without violating dose constraints. Both the distance between the IPL and rectum and the hip-to-hip patient width on planning CT scans were associated with the feasibility to plan an SIB (p = 0.002 and p = 0.0137, respectively). CONCLUSIONS On the basis of this small cohort, the distance between an intraprostatic lesion and the rectum most strongly predicted the ability to plan high-dose radiation to a dominant intraprostatic lesion. High-dose SIB planning seems possible for select intraprostatic lesions.

[1]  R. DiPaola,et al.  Contemporary risk profile of prostate cancer in the United States. , 2009, Journal of the National Cancer Institute.

[2]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial , 2003 .

[3]  Bruno Speleers,et al.  Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. , 2008, International journal of radiation oncology, biology, physics.

[4]  Daniel W. Miller,et al.  Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.

[5]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[6]  Xavier Leroy,et al.  Peripheral zone prostate cancers: Location and intraprostatic patterns of spread at histopathology , 2009, The Prostate.

[7]  Henning Salz,et al.  Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate cancer? , 2009, International journal of radiation biology.

[8]  G. Gustafson,et al.  Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study. , 2007, International journal of radiation oncology, biology, physics.

[9]  A. Hanlon,et al.  The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer , 2004, Cancer.

[10]  Tom W J Scheenen,et al.  IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. , 2006, International journal of radiation oncology, biology, physics.

[11]  Intra- and inter-radiation therapist reproducibility of daily isocenter verification using prostatic fiducial markers , 2006, Radiation oncology.

[12]  D. Kuban,et al.  Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. , 1987, Urology.

[13]  C. Reddy,et al.  Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10). , 2001, International journal of radiation oncology, biology, physics.

[14]  George Starkschall,et al.  Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[15]  S. Webb,et al.  Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. , 2002, The British journal of radiology.

[16]  M. Eble,et al.  Image-guided radiotherapy for prostate cancer , 2008, Strahlentherapie und Onkologie.

[17]  D P Dearnaley,et al.  Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. , 1999, The British journal of radiology.

[18]  Y. Yamada,et al.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[19]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[20]  Frederik Wenz,et al.  Intrafraction motion of the prostate during an IMRT session: a fiducial-based 3D measurement with Cone-beam CT , 2008, Radiation oncology.

[21]  J. McNeal,et al.  Patterns of spread of adenocarcinoma in the prostate as related to cancer volume , 2001, The Prostate.

[22]  A. D'Amico,et al.  Defining the Rectal Dose Constraint for Permanent Radioactive Seed Implantation of the Prostate , 2005 .

[23]  A. Zietman,et al.  Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Hsu,et al.  Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[25]  M. V. van Herk,et al.  Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). , 2005, International journal of radiation oncology, biology, physics.

[26]  J. Pouliot,et al.  Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. , 2004, International journal of radiation oncology, biology, physics.

[27]  G. Andriole,et al.  Influence of Local Tumor Control on Distant Metastases and Cancer Related Mortality After External Beam Radiotherapy for Prostate Cancer , 2008 .

[28]  B Pickett,et al.  Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. , 2001, International journal of radiation oncology, biology, physics.

[29]  L Verhey,et al.  Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. , 1999, International journal of radiation oncology, biology, physics.

[30]  Yoshiya Yamada,et al.  Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.

[31]  Leen Paelinck,et al.  The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  F Lohr,et al.  [Image-guided radiotherapy for prostate cancer]. , 2007, Aktuelle Urologie.

[33]  K. Yamada,et al.  Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. , 2003, The British journal of radiology.

[34]  Gabor Fichtinger,et al.  Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: early results of a phase I NCI study , 2007, Radiation oncology.

[35]  C. Kim,et al.  Localization of Prostate Cancer Using 3T MRI: Comparison of T2-Weighted and Dynamic Contrast-Enhanced Imaging , 2006, Journal of computer assisted tomography.

[36]  Cedric Yu,et al.  Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[37]  Vincenzo Valentini,et al.  Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. , 2002, International journal of radiation oncology, biology, physics.